Advertisement

Drugs

, Volume 75, Issue 2, pp 219–230 | Cite as

Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis

  • Esther S. Kim
  • Gillian M. Keating
Adis Drug Evaluation

Abstract

Pirfenidone (Esbriet®) is an orally administered, synthetic, pyridone compound that is approved for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU, and for the treatment of IPF in the USA. This article summarizes pharmacological, efficacy and tolerability data relevant to the use of pirfenidone in these indications. In the randomized, double-blind, placebo-controlled, multinational CAPACITY trials in patients with mild to moderate IPF, a significant reduction in the rate of decline in forced vital capacity (FVC) was seen with pirfenidone versus placebo in study 004 but not in study 006. Pirfenidone also reduced the rate of decline in FVC to a significantly greater extent than placebo in the randomized, double-blind, multinational ASCEND trial in this patient population. In addition, pirfenidone showed a significant treatment effect on the 6-min walking test distance and progression-free survival in the ASCEND trial and in a pooled analysis of the CAPACITY trials. Pirfenidone had a manageable tolerability profile in all three studies. Gastrointestinal and skin-related events (e.g. nausea, rash, photosensitivity reaction), which were the most commonly occurring treatment-emergent adverse events, were generally mild to moderate in severity. In addition, a prespecified mortality analysis across all three studies demonstrated a significant reduction in IPF-related and all-cause mortality with pirfenidone. In conclusion, oral pirfenidone is a valuable agent for use in patients with IPF.

Keywords

Idiopathic Pulmonary Fibrosis Forced Vital Capacity Usual Interstitial Pneumonia Idiopathic Pulmonary Fibrosis Patient Pirfenidone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. Esther S. Kim and Gillian M. Keating are salaried employees of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

References

  1. 1.
    Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.PubMedCrossRefGoogle Scholar
  2. 2.
    Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21(126):355–61.PubMedCrossRefGoogle Scholar
  3. 3.
    Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008. doi: 10.1186/1750-1172-3-8.PubMedCentralPubMedGoogle Scholar
  4. 4.
    European Respiratory Society. Interstitial lung diseases. In: Gibson GJ, Loddenkemper R, Sibille Y, Lundbäck B, editors. European lung white book: respiratory health and disease in Europe. Sheffield: European Respiratory Society; 2013. p. 256–69.Google Scholar
  5. 5.
    Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010;35(3):496–504.PubMedCrossRefGoogle Scholar
  6. 6.
    Sandbo N. Mechanisms of fibrosis in IPF. In: Meyer KC, Nathan SD, editors. Idiopathic pulmonary fibrosis: a comprehensive clinical guide. New York: Humana Press; 2014. p. 161–205.Google Scholar
  7. 7.
    Selman M, King TE Jr, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Katzenstein A-LA, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1301–15.PubMedCrossRefGoogle Scholar
  9. 9.
    Cottin V, Wijsenbeek M, Bonella F, et al. Slowing progression of idiopathic pulmonary fibrosis with pirfenidone: from clinical trials to real-life experience. Clin Investig. 2014;4(4):313–26.CrossRefGoogle Scholar
  10. 10.
    Carter NJ. Pirfenidone in idiopathic pulmonary fibrosis. Drugs. 2011;71(13):1721–32.PubMedCrossRefGoogle Scholar
  11. 11.
    European Medicines Agency. Esbriet (pirfenidone) hard capsules: EU summary of product characteristics. 2014. http://www.ema.europa.eu. Accessed 5 Jan 2015.
  12. 12.
    US FDA. Esbriet (pirfenidone) capsules: US prescribing information. 2014. http://www.accessdata.fda.gov. Accessed 5 Jan 2015.
  13. 13.
    US FDA. Two FDA drug approvals for idiopathic pulmonary fibrosis (IPF). 2014. http://blogs.fda.gov. Accessed 20 Oct 2014.
  14. 14.
    Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Conte E, Gili E, Fagone E, et al. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1–3):400–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;289(1):211–8.PubMedGoogle Scholar
  18. 18.
    Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation. 2000;24(5):477–91.PubMedCrossRefGoogle Scholar
  19. 19.
    Hostettler K, Zhong J, Tamm M, et al. Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis [abstract no. P763]. In: ERS international congress; 2014.Google Scholar
  20. 20.
    European Medicines Agency. Esbriet (pirfenidone): CHMP assessment report. 2011. http://www.ema.europa.eu. Accessed 21 Oct 2014.
  21. 21.
    Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol. 1999;276(2 Pt 1):L311–8.PubMedGoogle Scholar
  22. 22.
    Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem. 2000;204(1–2):119–26.PubMedCrossRefGoogle Scholar
  23. 23.
    He X, Long X, Wessendorf TE, et al. Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP) [abstract no. P764]. In: ERS international congress; 2014.Google Scholar
  24. 24.
    Mitani Y, Sato K, Muramoto Y, et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem Biophys Res Commun. 2008;372(1):19–23.PubMedCrossRefGoogle Scholar
  25. 25.
    Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. 2002;446(1):167–76.PubMedCrossRefGoogle Scholar
  26. 26.
    Giri SN, Leonard S, Shi X, et al. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol. 1999;18(3):169–77.PubMedGoogle Scholar
  27. 27.
    Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22(4):279–85.PubMedCrossRefGoogle Scholar
  28. 28.
    King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.PubMedCrossRefGoogle Scholar
  29. 29.
    Nagai S, Hamada K, Shigematsu M, et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med. 2002;41(12):1118–23.PubMedCrossRefGoogle Scholar
  30. 30.
    Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1061–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19(5):740–7.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    InterMune. InterMune reports phase 3 ASCEND trial results of pirfenidone in idiopathic pulmonary fibrosis (IPF) [media release], 25 Feb 2014. http://www.intermune.co.uk.
  35. 35.
    US National Institutes of Health. ClinicalTrials.gov. 2015. http://clinicaltrials.gov. Accessed 5 Jan.
  36. 36.
    Costabel U, Albera C, Bradford WZ, et al. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(3):198–205.PubMedGoogle Scholar
  37. 37.
    Kohlhaeufl MJ, Ingerl H, Bachnik M. Pirfenidone in idiopathic pulmonary fibrosis—description of a German cohort [abstract no. P3749]. In: ERS international congress; 2014.Google Scholar
  38. 38.
    MacQuarrie JL, Lebel F. Pirfenidone use in clinical practice: analysis of data from a Canadian patient support program for patients with idiopathic pulmonary fibrosis (INSPIRATION) [abstract no. A1428]. Am J Respir Crit Care Med. 2014;189(Meeting abstracts).Google Scholar
  39. 39.
    Nieto A, Valenzuela C, Rivera I, et al. Pirfenidone in idiopathic pulmonary fibrosis (ipf): Spanish experience with the European named patient program (npp) and Spanish patient progam (spp) [abstract no. A1418]. Am J Respir Crit Care Med. 2014;189 (Meeting abstracts).Google Scholar
  40. 40.
    Loeh B, Drakopanagiotakis F, Bandelli GP, et al. Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts [abstract no. 854923]. In: ERS international congress; 2014.Google Scholar
  41. 41.
    Wijsenbeek MS, Van Beek FT, Geel AL, et al. Pirfenidone in daily clinical use in patients with idiopathic pulmonary fibrosis in the Netherlands [abstract no. A4340]. Am J Respir Crit Care Med. 2013;187(Meeting abstracts).Google Scholar
  42. 42.
    Chaudhuri N, Duck A, Frank R, et al. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(1):224–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration. 2014. doi: 10.1159/000363064.Google Scholar
  44. 44.
    Bonella F, Wessendorf TE, Costabel U. Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis [article in German]. Dtsch Med Wochenschr. 2013;138(11):518–23.PubMedCrossRefGoogle Scholar
  45. 45.
    Ravaglia C, Gurioli C, Romagnoli M, et al. Pirfenidone treatment in idiopathic pulmonary fibrosis: an Italian case series [abstract no. P3370]. Eur Respir J. 2013;42(Suppl. 57):688s.Google Scholar
  46. 46.
    Nathan SD, Albera C, Bradford WZ, et al. Long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): integrated analysis of data from 4 clinical trials [abstract no. A1422]. Am J Respir Crit Care Med. 2014;189(Meeting abstracts).Google Scholar
  47. 47.
    Koschel D, Cottin V, Sköld M, et al. Pirfenidone post-authorization safety registry (PASSPORT)—interim analysis of IPF treatment [abstract no. 850348]. In: ERS international congress; 2014.Google Scholar
  48. 48.
    Passport Study. PASSPORT: post-authorisation safety study of Esbriet (pirfenidone): a prospective observational registry to evaluate long-term safety in a real-world setting. 2014. www.passportstudy.com. Accessed 21 Aug 2014.
  49. 49.
    Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31(4):375–91.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Xaubet A, Behr J, Bendstrup E, et al. Review of idiopathic pulmonary fibrosis diagnosis and management recommendations in Europe. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(4):249–61.PubMedGoogle Scholar
  51. 51.
    Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186(1):88–95.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Martinez FJ, de Andrade JA, Anstrom KJ, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2093–101.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77.PubMedCrossRefGoogle Scholar
  54. 54.
    Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.PubMedCrossRefGoogle Scholar
  55. 55.
    US FDA. FDA approves Esbriet to treat idiopathic pulmonary fibrosis [media release], 15 Oct 2014. http://www.fda.gov.
  56. 56.
    National Institute for Health and Care Excellence. Pirfenidone for treating idiopathic pulmonary fibrosis. 2013. http://www.nice.org.uk. Accessed 3 Sep 2014.
  57. 57.
    Swedish Respiratory Society. Vårdprogram för idiopatisk lungfibros [in Swedish]. 2012. http://www.slmf.se. Accessed 4 Sep 2014.
  58. 58.
    Xaubet A, Ancochea J, Bollo E, et al. Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Arch Bronconeumol. 2013;49(8):343–53.PubMedCrossRefGoogle Scholar
  59. 59.
    National Centre for Pharmacoeconomics Ireland. Cost-effectiveness of pirfenidone (Esbriet®) for the treatment of idiopathic pulmonary fibrosis. 2013. http://www.ncpe.ie. Accessed 4 Sep 2014.
  60. 60.
    National Institute for Health and Care Excellence. Pirfenidone for treating idiopathic pulmonary fibrosis: overview and resources. 2013. http://www.nice.org.uk. Accessed 3 Sep 2014.
  61. 61.
    Scottish Medicines Consortium. SMC advice for drugs accepted with a PAS: pirfenidone. 2013. http://www.scottishmedicines.org.uk. Accessed 9 Oct 2014.
  62. 62.
    PR Newswire. France’s economic committee (CEPS) authorizes reimbursement of Esbriet® (pirfenidone) [media release], 11 Sep 2012. http://www.prnewswire.com.
  63. 63.
    PR Newswire. InterMune announces publication of pricing and reimbursement conditions for Esbriet® (pirfenidone) in Italy [media release], 14 Jun 2013. http://www.prnewswire.com.
  64. 64.
    InterMune. A randomized, double-blind, placebo-controlled, phase 2 study of the safety and tolerability of N-acetylcysteine in patients with idiopathic pulmonary fibrosis with background treatment of pirfenidone [Clinicaltrialsregister.eu identifier 2012-000564-14] European Medicines Agency, Clinicaltrialsregister.eu. 2013. https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000564-14/DE. Accessed 10 Oct 2014.

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations